Edition:
United States

Juniper Pharmaceuticals Inc (JNP.OQ)

JNP.OQ on NASDAQ Stock Exchange Global Select Market

4.80USD
15 Dec 2017
Change (% chg)

$-0.20 (-4.00%)
Prev Close
$5.00
Open
$5.00
Day's High
$5.00
Day's Low
$4.65
Volume
16,814
Avg. Vol
4,551
52-wk High
$6.10
52-wk Low
$3.65

Latest Key Developments (Source: Significant Developments)

Juniper Pharmaceuticals reports third quarter results
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Juniper Pharmaceuticals Inc :Juniper Pharmaceuticals reports third quarter 2017 financial and operating results.Q3 loss per share $0.13.Q3 revenue rose 12 percent to $13 million.  Full Article

Juniper Pharmaceuticals announces strategic reprioritization
Monday, 18 Sep 2017 04:05pm EDT 

Sept 18 (Reuters) - Juniper Pharmaceuticals Inc :Juniper Pharmaceuticals announces strategic reprioritization.Juniper Pharmaceuticals Inc - ‍Company will begin to focus its research and development organization on JNP-0201 for hormone replacement therapy​.Juniper - ‍Actions are expected to result in cost savings that will position Juniper to achieve at least a cash flow neutral position for 2018​.Juniper Pharmaceuticals Inc - ‍As a result of focused research and development strategy, company will implement an approximately 8% headcount reduction​.Juniper Pharmaceuticals Inc - ‍Company also expects to reduce its overall new product research and development spend in connection with its revised focus​.Juniper Pharmaceuticals Inc - Bridget Martell, M.D., chief medical officer, will be stepping down from company effective today, September 18, 2017.Juniper Pharmaceuticals - Headcount reduction will result in estimated annual savings in personnel-related costs of about $1.9 million beginning in 2018.Juniper - Estimates it will incur charges of about $0.6 million to $0.7 million for one-time severance and other employee related costs in Q3.  Full Article

Juniper Pharmaceuticals reports Q1 loss per share $0.13
Thursday, 4 May 2017 07:45am EDT 

May 4 (Reuters) - Juniper Pharmaceuticals Inc : :Juniper pharmaceuticals reports first quarter 2017 financial and operating results.Q1 loss per share $0.13.Q1 revenue $11.2 million.Frank Condella will not seek re-election to co's board of directors.Juniper Pharmaceuticals Inc - expect to be in a position to file up to three ind's with U.S. Food and drug administration in first half of 2018.Q1 earnings per share view $-0.09, revenue view $11.3 million -- Thomson Reuters I/B/E/S.  Full Article

Juniper Pharmaceuticals Q4 EPS $0.88
Tuesday, 7 Mar 2017 06:00am EST 

Juniper Pharmaceuticals Inc : Juniper pharmaceuticals reports fourth quarter and full-year 2016 financial and operating results . Q4 earnings per share $0.88 . Q4 revenue rose 143 percent to $20.9 million . Juniper pharmaceuticals inc - expect to continue ind-enabling activities which could potentially support three ind filings in first half of 2018 .Juniper pharmaceuticals inc- "operating expense will increase modestly year over year" in 2017.  Full Article

Juniper Pharmaceuticals prototype formulation development for JNP-0301 is underway
Thursday, 5 Jan 2017 08:30am EST 

Juniper Pharmaceuticals Inc : Prototype formulation development for jnp-0301 is underway, with ind-enabling studies planned for 2017 . Company expects to initiate definitive sheep studies by year-end 2017 for jnp-0301 .Juniper pharmaceuticals inc- sheep studies could potentially enable an ind submission in first half of 2018 for jnp-0301.  Full Article

Juniper Pharma names Jeffrey Young as CFO
Friday, 23 Dec 2016 04:21pm EST 

Juniper Pharmaceuticals Inc : Juniper Pharmaceuticals -entered into employment agreement with Jeffrey Young pursuant to which Young will serve as co's new CFO effective Jan 1, 2017 .Juniper Pharmaceuticals - Young will succeed George O. Elston as Chief Financial Officer, principal financial officer, treasurer of co - SEC filing.  Full Article

Juniper Pharmaceuticals reports Q3 financial results
Tuesday, 15 Nov 2016 05:59am EST 

Juniper Pharmaceuticals Inc : Juniper Pharmaceuticals - To record $11 million payment,royalties for Oct as royalty income from monetization of U.S. Crinone royalty in Q4 of 2016 . Q3 earnings per share $0.02 . Juniper Pharmaceuticals reports third quarter 2016 financial results .Q3 revenue $11.6 million.  Full Article

Juniper Pharmaceuticals Q2 loss per share $0.16
Thursday, 4 Aug 2016 06:50am EDT 

Juniper Pharmaceuticals Inc : Juniper Pharmaceuticals reports second quarter 2016 financial results . Q2 revenue $11.9 million . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.16 . Q2 revenue view $9.5 million -- Thomson Reuters I/B/E/S . Anticipates full-year 2016 revenue growth in low- to mid-teen percentage range over 2015 result .Now anticipates full-year 2016 revenue growth in low- to mid-teen percentage range over 2015 results.  Full Article

Juniper Pharmaceuticals appoints CEO
Wednesday, 20 Jul 2016 06:50am EDT 

Juniper Pharmaceuticals Inc : Secor will also be appointed to board of directors . Juniper Pharmaceuticals appoints Alicia Secor president and chief executive officer . Secor will also be appointed to board of directors .Secor succeeds Frank Condella, who announced his intent to retire as Juniper's president and CEO earlier this year..  Full Article

Juniper Pharmaceuticals completes enrollment in phase 2b clinical trial of COl-1077, 10 pct lidocaine vaginal gel
Thursday, 7 Jul 2016 09:00am EDT 

Juniper Pharmaceuticals Inc : Juniper pharmaceuticals announces completion of enrollment in phase 2b clinical trial of col-1077 10% lidocaine vaginal gel for gynecologic procedure pain .Remains on track to report top-line data from study in q3 of 2016.  Full Article

BRIEF-Juniper Pharmaceuticals reports third quarter results

* Juniper Pharmaceuticals reports third quarter 2017 financial and operating results